Accelerating Early-Stage Drug Discovery:
How Novalix Integrates CDD Vault and StarDrop for Smarter R&D
Created by
Case Study
Early-stage drug discovery now demands more speed and precision than fragmented systems can deliver, and disconnected data is quietly slowing down the decisions that matter most for R&D teams.
Bringing a new drug to market has grown more difficult and expensive, and the pressure is compounding: research organizations now generate chemistry, biophysics, pharmacology, and DMPK data across multiple sites, instruments, and scientific disciplines, often within the same project week.
Without a shared, structured source of truth, teams still lose real time to searching hard drives, chasing email trails, and reformatting files before analysis can even begin, a drag that only grows across multi-site, multi-department projects and partner handoffs.
This case study follows one early-stage drug discovery organization as it connects chemistry, pharmacology, and molecular design data across departments and platforms, showing what changes when research teams finally work from one current, shared view of their science.
See how one drug discovery organization connected data across departments and sites to speed up R&D decisions.
"*" indicates required fields
What’s Inside:
A single source of truth
See how centralizing chemistry, biophysics, pharmacology, and DMPK data eliminates silos that slow down cross-department collaboration.
Faster, more confident decisions
Learn how built-in analysis and visualization tools turn raw research results into actionable insight without the usual wait.
Seamless platform integration
Discover how linking data management directly with molecular design and analysis tools removes manual export and import steps for good.
A model for multi-site collaboration
Understand how research teams spanning multiple geographies keep every department working from the same current data.